【肺癌】利用機器學習評估「Tarlatamab」在「小細胞肺癌」的上市後安全性

 【肺癌】利用機器學習評估「Tarlatamab」在「小細胞肺癌」的上市後安全性

 文章出處  

Frontiers in Pharmacology 

 

 原文標題  

Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events 

 

 文章序號  

11943 

 

智醫科學－AI醫療技術、應用與市場動態

Copyright ©2026 智醫科學 MEDai.tw All rights reserved.

The content of this site is intended for healthcare and medical professionals.